Sign up to save your podcasts
Or
Share NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
View all episodes
By NEJM Group
4.4
120120 ratings
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
JACC This Week
171 Listeners
Clinical Conversations
57 Listeners
Mayo Clinic Talks
289 Listeners
BMJ Best Practice Podcast
26 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Curbside Consults
90 Listeners
Leadership Conversations
5 Listeners
Annals On Call Podcast
191 Listeners
JAMA Medical News
88 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Cardionerds: A Cardiology Podcast
431 Listeners
The Curious Clinicians
372 Listeners
NEJM AI Grand Rounds
58 Listeners
Intention to Treat
32 Listeners
Not Otherwise Specified
49 Listeners